Skip to content

Pharminent

cropped-banner_frontpage_2026-07-11-2.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • SonoThera bags $125M series B to advance safer gene therapies
  • M&A / Deals

SonoThera bags $125M series B to advance safer gene therapies

BioSpace

Instead of using viral vectors, SonoThera's genetic medicines are delivered through an ultrasound-mediated technology that could help sidestep key safety issues with conventional delivery methods.

Gene Therapy Platform

Read full story

pharminent June 11, 2026 (Last updated: June 15, 2026)

BioSpace

Instead of using viral vectors, SonoThera’s genetic medicines are delivered through an ultrasound-mediated technology that could help sidestep key safety issues with conventional delivery methods.

Gene Therapy Platform

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
Next: Novartis gets win for another Avidity muscular dystrophy AOC

Related Stories

  • M&A / Deals

Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

pharminent July 10, 2026
  • M&A / Deals

GSK ends dementia alliance with Alector after setbacks

pharminent July 9, 2026
  • M&A / Deals

AstraZeneca, GSK intensify China ties with Sino Biopharm deals

pharminent July 8, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.